Microbot Medical Stock Discussion

$Microbot Medical (MBOT.US)$
Microbot Medical's Revolutionary Disposable Robotic Surgery System Awaits FDA Decision

$Microbot Medical (MBOT.US)$
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Tuesday, 10th December at 10:18 am
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical® Inc. (NASDAQ: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga A...

$Microbot Medical (MBOT.US)$
Microbot Medical Files FDA Application for Revolutionary Disposable Robotic Surgery System

$Microbot Medical (MBOT.US)$ Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
2 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial
FDA 510(k) Clearance Anticipated During the Second Quarter of 2025
Company Preparing to Commence Commercialization Following FDA 510(k) Clearance

$Microbot Medical (MBOT.US)$
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected
Tuesday, 3rd December at 8:45 am
PALM BEACH, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence, machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilita...

$Microbot Medical (MBOT.US)$
BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinica...

$Microbot Medical (MBOT.US)$
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
Microbot Medical Inc. (Nasdaq: MBOT) has successfully completed enrollment and follow-up for all patients in its ACCESS-PVI human clinical trial for the LIBERTY® Endovascular Robotic Surgical System. The company is on track to file its 510(k) submission with the FDA by the end of 202...

$Microbot Medical (MBOT.US)$ Reuters· 5 mins ago
Microbot Medical (MBOT.US)
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in Its Pivotal Human Clinical Trial for the Liberty Endovascular Robotic Surgical System! Intends to submit to FDA for 510 (K) by EOY

$Microbot Medical (MBOT.US)$
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

$Microbot Medical (MBOT.US)$ Reuters
·1 min ago
Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the Liberty® Endovascular Robotic System